Table 1.
Baseline characteristics of patients reported to the CIBMTR from 2008–2013
| Number of patients | 6523 | 6574 | |
| Age at HCT, years | |||
| Median (range) | 45 (< 1–79) | 46(<1–80) | |
| <10 | 1046(16) | 1047(16) | |
| 10–19 | 635(10) | 611(9) | |
| 20–39 | 1184(18) | 1123(17) | |
| 40–59 | 2333 (35) | 2421 (37) | |
| ≥60 | 1325(20) | 1372(20) | |
| Male Sex | 3790 (58) | 3828 (58) | |
| Karnofsky score 90–100% | 4426 (68) | 4476(68) | |
| Missing | 118(2) | 128(2) | |
| HCT-CI | |||
| 0 | 3656 (56) | 3645 (55) | |
| 1–2 | 1246(19) | 1279(19) | |
| 3 or more | 1473 (23) | 1511 (23) | |
| Missing | 148 (2) | 139(2) | |
| Disease / Disease Status at Time of Transplant | |||
| Advanced3/Missing | 518(8) | 566(9) | |
| Advanced3 | 75(1) | 75(1) | |
| Advanced6 | 55(1) | 59(1) | |
| Myelodysplastic Syndrome | 910(14) | 921 (14) | |
| REL resistant | 54 (1) | 53(1) | |
| Other leukemias7 | 280 (4) | 300 (5) | |
| Multiple Myeloma | 63(1) | 69(1) | |
| Myeloproliferative Syndromes | 361 (6) | 348 (5) | |
| Aplastic Anemia/Abnormalities of Erythrocytes | 422 (6) | 395(6) | |
| Histiocytic disorders | 85(1) | 71(1) | |
| Inherited problems of metabolism | 131 (2) | 128 (2) | |
| Severe Combined Immunodeficiency Disease | 233 (4) | 228 (3) | |
| Prior Autologous Transplant | 314(5) | 330(5) | |
| Recipient Hepatitis B/C status | |||
| Hepatitis B positive or Hepatitis B and C positive | 272 (4) | 249 (4) | |
| Hepatitis C positive | 45(1) | 47(1) | |
| Hepatitis B and C negative | 5981 (92) | 6041 (92) | |
| Not tested/Inconclusive | 225(3) | 237 (4) | |
| Recipient CMV Status Positive | 3918(60) | 3899 (59) | |
| Not tested/Inconclusive | 84 (<1) | 87 (<1) | |
| Lines of chemotherapy prior to HCT | |||
| Median (range) | 2(0–13) | 2(0–12) | |
| 08 | 1235(19) | 1195(18) | |
| 1 | 1564(24) | 1614(25) | |
| 2+ | 3616(55) | 3638 (55) | |
| Missing | 108(2) | 127(2) | |
| Donor and Graft Type | |||
| Cord Blood | |||
| HLA unknown | 254 (4) | 231 (4) | |
| Bone Marrow | |||
| Other Relative | 163(2) | 158(2) | |
| Peripheral Blood | |||
| Other Relative | 182(3) | 181(3) | |
| Conditioning Intensity/Regimens | |||
| MAC-TBI | |||
| <=12 Gy TBI/Cy | 514(8) | 533(8) | |
| >12GyTBI/Cy | 340 (5) | 348 (5) | |
| <=12GyTBI/Cy/Others | 244 (4) | 256 (4) | |
| >12GyTBI/Cy/Others | 348 (5) | 365(6) | |
| <=12 Gy TBI ± Others | 112(2) | 92(1) | |
| >12GyTBI± Others | 114(2) | 135(2) | |
| MAC-Chemo | |||
| Bu/Cy with PK monitoring | 574 (9) | 556(8) | |
| Bu/Cy without PK monitoring | 433 (7) | 480 (7) | |
| Bu/Cy/Others with PK monitoring | 91(1) | 88(1) | |
| Bu/Cy/Others without PK monitoring | 54(1) | 55(1) | |
| Bu/Flu with PK monitoring | 451 (7) | 453 (7) | |
| Bu/Flu without PK monitoring | 307 (5) | 326 (5) | |
| Bu/Flu/Others with PK monitoring | 48(1) | 51(1) | |
| Bu/Flu/Others without PK monitoring | 46(1) | 45(1) | |
| Bu/Mcl/Othcrs with PK monitoring | 46(1) | 48(1) | |
| Bu/Mel/Others without PK monitoring | 15 (<1) | 17 (<1) | |
| Bu/Others with PK monitoring | 28 (<1) | 38(1) | |
| Bu/Others without PK monitoring | 51(1) | 36(1) | |
| Thio/Others (non Bu) | 125 (2) | 120 (2) | |
| Others | 83(1) | 67(1) | |
| Bu-containing missing PK information | 2(<1) | 4(<1) | |
| R1C-TB1 | 185(3) | 188(3) | |
| RIC-Chemo | |||
| Mel/Others or BEAM/CBV-like | 618(9) | 612(9) | |
| Bu/Others | 666(10) | 685(10) | |
| NST or No regimen given9 | 1028(16) | 976(15) | |
| ATG/Alemtuzumab | |||
| ATG | 2192 (34) | 2129(32) | |
| Alemtuzumab | 374 (6) | 357(5) | |
| Both ATG and Alemtuzumab | 1(<1) | 1(<1) | |
| Neither ATG or Alemtuzumab | 3956(61) | 4087(62) | |
| GVHD prophylaxis | |||
| Tac | 530 (8) | 565 (9) | |
| CSA | 426 (7) | 438(7) | |
| Ex-vivo T-cell Depletion | 90(1) | 68(1) | |
| CD34 selection | 105(2) | 119(2) | |
| Post-transplant Cyclophosphamide | 69(1) | 74(1) | |
| Others | 81(1) | 93(1) | |
| Sinilimus used in GVHD prophylaxis | 514(8) | 556 (8) | |
| Ursodiol used in GVHD prophylaxis | 383 (6) | 381 (6) | |
| Median follow-up of survivors (range), months | 43 (3–79) | 38 (3–79) | |
Abbreviations: ATG=anti-thymoglobulin; BEAM= carmustine, etoposide, cytarabine, melphalan;Bu=busulfan; BM=bone marrow; CBV=cyclophosphamide, carmustine, etoposide;CMV=cytomegalovirus; Cy=cyclophosphamide; CSA=cyclosporine A; Flu=fludarabine; GVHD=graft vs host disease; HCT=hematopoietic cell transplantation; HCT-CI=HCT-Comorbidity index; MAC=myeloablative conditioning; Mel=melphalan; MMF=mycophenolate mofetil; MTX=methotrexate; NST=Non-myeloablative stem cell transplant; PB=peripheral blood; PIF=primary induction failure; PK=pharmacokinetic; REL=relapsed; RIC=reduced intensity conditioning; Thio=thiotepa; Tac=tacrolimus; TBI=total body irradiation; URD=unrelated donor.
Early: CR1
Intermediate: CR2+
Advanced: Active Leukemia
Early: Chronic phase 1, hematologic complete remission
Intermediate: Chronic phase 2+
Advanced: Accelerated phase, blast crisis
Other Leukemias included: CLL, NOS; hairy cell leukemia; other leukemia, specify; CLL B-cell; CLL T-cell; PLL B cell; PLL T cell
Includes N=1693 non-malignant diseases
All patients who received no conditioning regimen had Severe Combined Immunodeficiency Diseases